Quick Search
Furosemide is a loop diuretic medication that increases the amount of water and electrolytes removed from the body through urine.
Furosemide belongs to the sulfonamide-derived class of diuretics and is one of the most widely recognized medicines used to reduce excess fluid accumulation.
Furosemide acts primarily in the thick ascending limb of the loop of Henle in the kidney.
CAS Number: 54-31-9
Molecular Formula: C12H11ClN2O5S
Molecular Weight: 330.74
EINECS Number: 200-203-6
Synonyms: Furosemide, 54-31-9, Frusemide, Lasix, Furanthril, Furosemid, Errolon, Seguril, Transit, Aisemide, Beronald, Desdemin, Eutensin, Frusemin, Fuluvamide, Furanthryl, Furantril, Furesis, Fursemide, Lasilix, Lowpstron, Macasirool, Prefemin, Radonna, Rosemide, Trofurit, Fulsix, Katlex, Lasex, Frusetic, Fursemid, Logirene, Marsemide, Frusid, Mirfat, Oedemex, Furosedon, Urosemide, Aluzine, Dryptal, Frusemid, Profemin, Disal, Diural, Rusyde, Hydro-rapid, Durafurid, Fuluvamine, Furosemidum, Hydroled, Endural, 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid, Furosemida, LB 502, LB-502, 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid, NCI-C55936, Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]-, DTXSID6020648, FUROSCIX, 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid, 5-(Aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoic acid, Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure, 4-Chloro-2-((furan-2-ylmethyl)amino)-5-sulfamoylbenzoic acid, 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid, Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl-, 7LXU5N7ZO5, NSC-269420, Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)-, 5-(Aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)benzoic acid, DTXCID80648, CHEBI:47426, NSC269420, Tenkofruse, Aquamed, Frumax, Frusol, Froop, Disal Injection, Lasix Packets, Salix Tablets, Lasix ret, SK-Furosemide, Furosemide 1%, Furos-A-Vet, Aluzine 20, Aluzine 40, Lasix Syrup 1%, Aluzine 500, Salix Injection 5%, Furosemide Syrup 1%, Furosemide Injection 5%, RefChem:607846, C03CA01, furosemide injection 80 mg/ 10 mL, 200-203-6, methforylthiazidine, Fusid, Salix, Promedes, Lazix, Frusenex, Furanturil, Lowpston, Furomex, Impugan, Uremide, Uresix, Yidoli, Furix, Laxur, Urian, Apo-Frusemide, Anfuramaide, Arasemide, Bioretic, Disemide, Diurapid, Diurolasa, Diusemide, Fluidrol, Frusedan, Furobeta, Furodiurol, Furodrix, Furorese, Furosemix, Furoside, Furosifar, Furovite, Fursemida, Hissuflux, Jenafusid, Lasiletten, Moilarorin, Novosemide, Protargen, Radisemide, Selectofur, Sigasalur, Spirofur, Synephron, Zafimida, Aldalix, Aquarid, Aquasin, Cetasix, Dirine, Discoid, Diurin, Diusil, Diuzol, Dranex, Edemid, Edenol, Farsix, Franyl, Frumex, Frumide, Frusema, Furetic, Furfan, Furmid, Furocot, Furomen, Furosan, Furose, Furosix, Furoter, Fursol, Kofuzon, Kolkin, Kutrix, Lasemid, Liside, Luscek, Nelsix, Odemase, Odemex, Promide, Puresis, Radouna, Salurex, Salurid, Uridon, Uritol, Aldic, Depix, Desal, Eliur, Fluss, Furex, Golan, Nadis, Retep, Rosis, Vesix, Mita, Apo-Furosemide, Furo-puren, Lasix Retard, less Diur, Neo-renal, Furo-Basan, Furosemidu, Urex-M, Nephron, Furomide M.D., 5-(Aminosulfonyl)-4-chloro-2-[(2-furylmethyl)amino]benzoic acid, Lasix (TN), Diumide-K, 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid, CHEMBL35, MFCD00010549, Furosemidu [Polish], 4-chloro-2-{[(furan-2-yl)methyl]amino}-5-sulfamoylbenzoic acid, CAS-54-31-9, Furosemidum [INN-Latin], 4-chloro-2-(2-furylmethylamino)-5-sulfamoyl-benzoic acid, Furosemida [INN-Spanish], NCGC00016241-06, Sal diureticum, Furosemide "mita", FUN, 4-chloro-2-[(2-furylmethyl)amino]-5-sulfamoylbenzoic acid, Furosemide mita, Furosemide oral, 5-(aminosulfonyl)-4-chloro-2-[(furan-2-ylmethyl)amino]benzoic acid, SMR000058202, CCRIS 1951, furosemide ''mita'', HSDB 3086, SR-01000765380, EINECS 200-203-6, Hoe-058A, UNII-7LXU5N7ZO5, NSC 269420, BRN 0840915, Tenkafruse, Neosemid, Zafurida, Fursemide, Diurapid, Dryptal, Furosemide RS, Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German], Furosemide CRS, 5-(AMINOSULFONYL)-4-CHLORO-2-((2-FURYLMETHYL)AMINO)BENZOIC ACID, Frumax, Frusid, 4-CHLORO-N-FURFURYL-5-SULFAMOYLANTHRANILIC ACID;5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID;5-[AMINOSULFONYL]-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID;LABOTEST-BB LT00244801;FUROSEMIDE;FUROSEMIDE METHANOL SOLUTION;FUROSEMIDE, RELATED COMPOUND B 4-CHLORO-5-SULFAMOYLANTHRANILIC ACID USP STANDARD;FUROSEMIDE, EP STANDARD
Furosemide, is a class of efficient sulfonamide diuretics acting on the medullary loop of the ascending branch of the medulla,it has a strong and short-term diuretic effect,which can increase the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphate and so on.
Furosemide Mainly inhibits Na + and Cl-reabsorption in medullary and cortex of the medullary loop ascending branch crude segment, it can promote the excretion of sodium, chloride and potassium and affect the formation of renal medullary high osmotic pressure,it can interfer the process of concentration and dilution of urine, and it can increase urine output.
Furosemide can inhibit the activity of prostaglandin decomposition enzyme ,make the content of prostaglandin E2 increase,it has effect on expansion of blood vessels, it also plays a role in the proximal tubule, glomerular filtration,it can increase renal blood flow,and adjust renal blood flow distribution,and reduce blood flow so that the cortex surface blood flow increases,it promotes diuresis, its effect is fast and strong, it is used for other diuretics invalid cases.
Clinically it is used for the treatment of cardiac edema, renal edema, cirrhosis ascitic fluid, peripheral edema caused by dysfunction or vascular disorders , and it may contribute to an upper urinary tract stones excretion.
Furosemide also can accelerate the excretion of toxic substances in cerebral edema in poisoning.
Note that when the diuretic furosemide is used, since the excretion of urine Cl-, Na +, K +, H + is increasing, while the excretion of HCO3-is not increasing, long-term repeated drug use or large quantities of drugs can cause low salt syndrome, low chlorine and low potassium alkalosis.
Furosemide is also commonly known by the synonym frusemide.
Furosemide has the molecular formula C12H11ClN2O5S and a molecular weight of approximately 330.74 g/mol.
Furosemides CAS Registry Number is 54-31-9, which is used to identify the compound in pharmaceutical, chemical, and scientific databases.
Furosemide is generally described chemically as 4-chloro-2-[(2-furanylmethyl)amino]-5-sulfamoylbenzoic acid.
The molecule contains several important functional groups, including a carboxylic acid, sulfonamide, aromatic chloride, and furan-containing structure.
These structural features contribute to its physicochemical properties and its interaction with renal transport proteins.
The molecule contains both polar and relatively hydrophobic regions, which influence its solubility and distribution.
Furosemide inhibits the sodium-potassium-chloride cotransporter, commonly referred to as NKCC2.
Blocking this transporter reduces the reabsorption of sodium and chloride from the tubular fluid.
As sodium reabsorption decreases, water excretion increases.
Furosemide produces the characteristic diuretic effect of furosemide.
The increased urine production can help reduce excess fluid in tissues and the circulation.
Furosemide also increases the urinary excretion of potassium, calcium, and magnesium.
For this reason, electrolyte levels may need to be monitored during treatment, particularly when higher doses or prolonged therapy are involved.
Furosemides effect on calcium excretion also distinguishes loop diuretics from some other classes of diuretics.
Furosemide has a rapid and relatively strong diuretic effect compared with many other commonly used diuretics.
The onset and duration of action depend on the route of administration and formulation.
Oral and injectable preparations are available in clinical practice.
Furosemide is primarily used when the body contains excess fluid, a condition commonly described as edema.
Edema can occur when fluid accumulates in tissues because of heart, kidney, liver, or other medical problems.
By increasing urine production, furosemide can help remove this excess fluid.
Furosemide is commonly used in the management of edema associated with congestive heart failure.
Reduced cardiac pumping capacity can contribute to fluid retention and swelling.
Diuretic therapy can reduce fluid overload and relieve symptoms associated with congestion.
Furosemide can also be used for edema associated with renal disorders.
Certain kidney diseases can cause the body to retain sodium and water.
Furosemide may be prescribed to increase fluid elimination when clinically appropriate.
Another application is the treatment of edema associated with liver disease.
Liver disorders can contribute to fluid accumulation, including abdominal fluid known as ascites.
Furosemide may be used as part of a broader treatment strategy under medical supervision.
Furosemide can also be used in the treatment of acute pulmonary edema.
In this situation, fluid accumulation in the lungs can cause severe breathing difficulty.
Intravenous furosemide may be used in appropriate clinical circumstances to promote rapid diuresis.
The medication can be administered orally or intravenously, with other routes used in specific formulations or circumstances.
Intravenous administration can produce a faster effect than oral administration.
The appropriate route depends on the patient's clinical condition and the intended therapeutic response.
Furosemide has also been used in acute clinical situations involving significant fluid overload.
Furosemides strong diuretic action can be useful when rapid removal of excess fluid is clinically necessary.
Treatment requires appropriate monitoring because excessive fluid removal can produce dehydration and electrolyte disturbances.
Furosemide has been used in hypertension management, although its role depends on the patient's condition and the treatment strategy.
By increasing sodium and water excretion, furosemide can reduce circulating fluid volume.
Other antihypertensive medications are often preferred for uncomplicated long-term hypertension.
Furosemide has also been investigated and used in renal replacement and critical-care settings.
Furosemide may be administered to patients with substantial fluid accumulation when residual kidney function allows a diuretic response.
Its use in these situations depends on the underlying kidney function and clinical objectives.
The pharmacological action of furosemide is strongly related to its ability to reach the renal tubular lumen.
Furosemide is transported into the proximal tubule through organic anion transport systems.
From there, it reaches its principal site of action in the thick ascending limb.
Furosemide binds to the chloride-binding site of the NKCC2 transporter.
This prevents normal transport of sodium, potassium, and chloride across the tubular epithelial cells.
The resulting reduction in electrolyte reabsorption increases their delivery into the urine.
Because the thick ascending limb normally contributes significantly to the kidney's ability to generate a concentration gradient, furosemide also affects urine-concentrating mechanisms.
This contributes to its strong diuretic action.
The overall effect is increased sodium and water elimination.
Furosemide is relatively highly protein-bound in the bloodstream.
Furosemide is transported to the kidneys where its pharmacological action occurs.
Its pharmacokinetic behavior can be altered by kidney function and other medications.
The drug is eliminated partly through renal and non-renal pathways.
Changes in kidney function can affect the response to treatment and may require adjustment of the therapeutic approach.
Clinical monitoring is therefore important in patients with impaired renal function.
Furosemide is available in several pharmaceutical dosage forms.
These include tablets, oral solutions, and injectable preparations depending on the market and manufacturer.
Different formulations are designed for different clinical situations.
Furosemide is also an important subject in pharmaceutical formulation research.
Researchers investigate its dissolution, stability, bioavailability, and compatibility with excipients.
These factors influence the performance of oral dosage forms.
Furosemide has relatively limited and variable oral bioavailability.
The amount absorbed can differ between individuals and can be influenced by gastrointestinal conditions and other factors.
This variability is one reason clinical response can differ between patients.
Furosemide has been studied extensively in pharmacokinetic research.
Researchers investigate absorption, distribution, metabolism, and elimination after different routes of administration.
These studies help establish appropriate dosing strategies.
Furosemide is also widely used as a reference compound in pharmaceutical analysis.
Analytical laboratories can determine its concentration in pharmaceutical formulations using chromatographic and spectroscopic techniques.
This is important for quality control and formulation development.
High-performance liquid chromatography, or HPLC, is commonly used for furosemide analysis.
Chromatographic methods can separate furosemide from excipients, degradation products, and related substances.
These methods are useful for pharmaceutical quality-control testing.
Furosemide can also be analyzed using UV-visible spectrophotometry because its aromatic and conjugated structural features absorb ultraviolet radiation.
Spectrophotometric methods can provide relatively straightforward quantitative measurements.
However, chromatographic techniques generally offer greater selectivity in complex samples.
Furosemide has been investigated for drug stability under different environmental conditions.
Temperature, humidity, light, pH, and formulation composition can influence chemical stability.
Stability studies help determine suitable storage conditions and shelf life.
Furosemide can undergo chemical degradation under certain conditions.
Hydrolysis, photochemical processes, and other degradation pathways have been examined in pharmaceutical research.
Understanding these pathways is important for maintaining product quality.
The molecule's chemical behavior is also relevant to pharmaceutical impurity profiling.
Manufacturers and analytical laboratories monitor related substances and degradation products to ensure that medicines meet quality specifications.
Validated analytical methods are used for this purpose.
Furosemide is an important compound in clinical pharmacology research.
Furosemides strong and well-characterized mechanism makes it useful for studying renal sodium handling and fluid balance.
Research involving the drug has contributed substantially to understanding renal physiology.
Furosemide has also been used in research concerning kidney function and electrolyte transport.
Because furosemide directly affects a major renal transporter, it can help researchers investigate sodium, potassium, and chloride handling by the nephron.
This makes it a useful pharmacological tool in renal research.
Furosemide has also been investigated in experimental models of heart failure and fluid overload.
Researchers use it to study changes in fluid balance, renal responses, and cardiovascular physiology.
These studies complement its established clinical role.
The drug can influence the renin-angiotensin-aldosterone system indirectly.
Increased sodium loss and reduced circulating volume can stimulate compensatory hormonal responses.
This is one reason the physiological effects of furosemide extend beyond simply increasing urine volume.
Furosemide can also increase prostaglandin-related renal effects.
Prostaglandin pathways can influence renal blood flow and the diuretic response.
This contributes to some of the drug's pharmacological interactions.
The medication has been studied extensively in cardiorenal medicine.
Heart and kidney function are closely connected through mechanisms controlling sodium and water balance.
Furosemide is an important therapeutic tool in situations where fluid accumulation occurs across this system.
Furosemide has also been used in veterinary medicine.
Veterinarians may use it for fluid accumulation and cardiovascular conditions in animals when clinically appropriate.
Veterinary formulations and dosing requirements differ from human treatment and require professional supervision.
Furosemide is also relevant to sports medicine and anti-doping control because it can increase urine production.
Furosemide is prohibited in competitive sport under anti-doping rules because diuretics can potentially be used to manipulate body weight or urine concentration and may interfere with detection of other substances.
Its use in athletes therefore requires careful attention to applicable anti-doping regulations.
Furosemide can also be used as a research tool in renal physiology experiments.
Researchers can administer the compound to investigate transporter activity and changes in electrolyte excretion.
Furosemides well-defined mechanism makes it particularly valuable in experimental kidney research.
Furosemide is a loop diuretic and sulfonamide-derived pharmaceutical compound whose primary pharmacological effect is inhibition of the renal NKCC2 sodium-potassium-chloride cotransporter.
Its major clinical applications involve the treatment of fluid retention, edema, heart-failure-associated congestion, renal or hepatic fluid accumulation, and acute pulmonary edema, while its broader scientific applications include pharmaceutical analysis, formulation research, renal physiology, pharmacokinetics, and veterinary medicine.
Its strong effect on electrolyte and water balance also means that it is a clinically significant drug requiring appropriate medical supervision rather than a compound intended for unsupervised use.
Melting point: 220 °C (dec.) (lit.)
Boiling point: 582.1±60.0 °C(Predicted)
Density: 1.606
refractive index: 1.6580 (estimate)
Flash point: 11 °C
storage temp.: 2-8°C
solubility: Practically insoluble in water, soluble in acetone, sparingly soluble in ethanol (96 per cent), practically insoluble in methylene chloride. It dissolves in dilute solutions of alkali hydroxides.
form: powder
pka: pKa 3.8 (Uncertain)
color: White to Off-White
biological source: rabbit
Water Solubility: Soluble in acetone, DMF or methanol. Slightly soluble in water
Merck: 14,4309
Henry's Law Constant: 2.5×1010 mol/(m3Pa) at 25℃, HSDB (2015)
BCS Class: 2 (CLogP), 4 (LogP)
Stability: Stable, but light sensitive, air sensitive and hygroscopic. Incompatible with strong oxidizing agents.
Major Application: pharmaceutical
pharmaceutical smala molecule
InChI: 1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
InChIKey: ZZUFCTLCJUWOSV-UHFFFAOYSA-N
SMILES: NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl
Furosemide is an analytical reference standard categorized as a diuretic.
Formulations containing diuretics, including furosemide, have been misused in sports for weight reduction and as masking agents in humans and to prevent exercise-induced pulmonary hemorrhage in racehorses.
Furosemide is intended for use in analytical forensic applications.
Furosemide is also available as a general research tool .
Furosemide increased risk of ototoxicity with aminoglycosides, polymyxins and vancomycin; avoid with lymecycline.
Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
Furosemide enhanced hypotensive effect; increased risk of first dose hypotensive effect with alpha-blockers; increased risk of ventricular arrhythmias with sotalol if hypokalaemia occurs.
Furosemide increased risk of ventricular arrhythmias with amisulpride or pimozide (avoid with pimozide) if hypokalaemia occurs; enhanced hypotensive effect with phenothiazines.
Ciclosporin: variable reports of increased nephrotoxicity, ototoxicity and hepatotoxicity.
Furosemide concentration of furosemide increased by dasabuvir, ombitasvir and paritaprevir - reduce furosemide dose; increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
Furosemide is one of the most extensively studied loop diuretics in modern pharmacology.
Furosemides strong natriuretic effect distinguishes it from milder diuretics that primarily act in other regions of the nephron.
It has therefore become an important compound in both clinical medicine and renal physiology research.
Furosemide belongs to the anthranilic acid derivative group of loop diuretics.
Furosemides chemical structure contains an anthranilic acid framework together with a sulfonamide group and a furan-containing substituent.
This structural arrangement is closely related to its interaction with renal electrolyte transport mechanisms.
The molecule contains a chlorine atom attached to its aromatic ring.
Furosemide also contains nitrogen, oxygen, sulfur, and carbon atoms arranged into several chemically distinct functional groups.
These features influence its acidity, solubility, ionization, and pharmaceutical behavior.
Furosemide is a weak organic acid because of its carboxylic acid group.
Furosemides ionization state can change according to the surrounding pH.
This property is relevant to its solubility, absorption, formulation, and analytical determination.
Furosemide is generally described as a white or almost white crystalline powder in its pure form.
It has limited solubility in water, although its solubility can vary depending on pH and formulation conditions.
This physicochemical behavior is important when designing oral pharmaceutical products.
Furosemide's low aqueous solubility can influence its dissolution rate.
Dissolution is an important step before an orally administered solid drug can be absorbed.
Pharmaceutical scientists therefore investigate particle size, excipients, pH, and formulation technology to improve drug performance.
The drug is absorbed from the gastrointestinal tract after oral administration.
However, absorption can be variable between individuals and between different formulations.
This variability contributes to differences in the intensity of the diuretic response.
Food can influence the absorption characteristics of orally administered furosemide.
The extent and timing of absorption may differ depending on administration conditions.
Clinical treatment therefore generally follows the dosing instructions associated with the specific formulation.
After absorption, a substantial proportion of furosemide is bound to plasma proteins.
Protein binding influences its distribution and availability for transport into the kidney.
Changes in protein concentration or displacement by other substances can potentially affect its pharmacokinetic behavior.
Furosemide reaches the kidney through the circulating bloodstream.
Because it is strongly protein-bound, it is not filtered freely through the glomerulus to the same extent as small unbound molecules.
Instead, active secretion into the proximal tubule plays an important role in delivering the drug to its site of action.
Organic anion transport systems are involved in the renal secretion of furosemide.
Transporters in the proximal tubule move the drug from the blood into the tubular fluid.
This allows furosemide to reach the luminal side of the NKCC2 transporter.
The drug acts primarily from the luminal side of the thick ascending limb.
This is a key reason why renal secretion is important for its pharmacological activity.
If the drug cannot reach the tubular lumen efficiently, its diuretic effect may be reduced.
The thick ascending limb normally reabsorbs a significant fraction of filtered sodium and chloride.
Furosemide also contributes to the establishment of the osmotic gradient that enables the kidney to concentrate urine.
Furosemide disrupts this process by blocking NKCC2.
The NKCC2 transporter simultaneously moves sodium, potassium, and chloride ions into renal epithelial cells.
Furosemide interferes with this transport process.
The resulting increase in electrolyte delivery to the urine produces strong natriuresis and diuresis.
Because NKCC2 is also involved in potassium recycling within the thick ascending limb, furosemide changes the electrical and ionic environment of the renal tubule.
This contributes to increased urinary calcium and magnesium loss.
These effects are important when considering long-term treatment and electrolyte monitoring.
Furosemide can therefore produce hypokalemia, meaning abnormally low blood potassium levels.
The risk depends on factors such as dose, duration of therapy, dietary intake, kidney function, and other medications.
Clinical monitoring may be necessary in patients receiving substantial or prolonged diuretic therapy.
Furosemide can also increase urinary calcium excretion.
This property has been studied extensively in renal physiology.
Furosemide contrasts with thiazide diuretics, which generally reduce urinary calcium excretion.
Furosemide can increase magnesium excretion as well.
Significant magnesium loss can contribute to electrolyte disturbances in susceptible patients.
This is another reason why electrolyte status may be monitored during treatment.
The drug can cause substantial sodium loss.
Sodium loss is central to its therapeutic effect in fluid-overloaded patients.
However, excessive sodium and water loss can result in dehydration or low blood volume.
Furosemide can also reduce circulating blood volume.
Furosemide can decrease venous pressure and reduce congestion in patients with fluid-overload conditions.
The reduction in congestion is one of the major reasons for its clinical use in heart failure.
In acute pulmonary edema, reducing excessive circulatory volume can help decrease pulmonary vascular pressure.
Furosemide can contribute to improvement in pulmonary congestion when furosemide is clinically appropriate.
The overall treatment of acute pulmonary edema may involve several interventions depending on the cause and severity.
Furosemide is commonly administered by intravenous injection or infusion when a rapid effect is required.
The intravenous route bypasses gastrointestinal absorption and can provide more predictable delivery.
Furosemide makes it particularly useful in certain acute-care situations.
Oral furosemide is commonly used for ongoing fluid management.
The dose and frequency depend on the clinical condition and the patient's response.
Because individual responses vary, treatment is generally adjusted according to clinical findings and laboratory measurements.
Furosemide can produce a dose-dependent increase in urine output over an appropriate therapeutic range.
Higher doses generally produce greater natriuresis, although the relationship is influenced by kidney function and other factors.
Very high doses do not necessarily provide proportionally greater benefit and can increase adverse effects.
Patients with impaired kidney function may require different dosing strategies.
Reduced renal function can alter drug delivery to the tubular site of action and change the required dose.
Clinical decisions therefore depend on kidney function and the underlying cause of fluid retention.
Furosemide is also relevant to acute kidney injury research.
Researchers have investigated whether diuretics can alter urine production in patients with impaired renal function.
Increasing urine output does not necessarily mean that underlying kidney injury has been reversed.
The drug can be useful for managing fluid balance even when kidney function is impaired, provided that sufficient renal responsiveness remains.
However, its effect may become reduced in severe renal dysfunction.
Clinical management must therefore distinguish between increasing urine output and improving renal function.
Furosemide has been extensively studied in heart failure.
Heart failure can activate hormonal systems that promote sodium and water retention.
Furosemide counteracts the resulting fluid accumulation by increasing renal sodium and water excretion.
Furosemide can also be combined with other diuretic classes in certain treatment strategies.
Combining drugs that act at different nephron sites can produce a stronger diuretic response in resistant fluid overload.
Such combinations require careful monitoring because electrolyte abnormalities can become more likely.
Furosemide can interact pharmacologically with other medicines.
Interactions may involve changes in renal function, electrolyte balance, blood pressure, or drug concentration.
The significance of an interaction depends on the specific medication combination and patient characteristics.
One clinically important consideration is the potential for increased ototoxicity at high exposure.
Rapid intravenous administration and high doses have historically been associated with an increased risk of hearing-related adverse effects, particularly in vulnerable patients.
Appropriate administration rates and clinical monitoring are therefore important when high-dose intravenous therapy is required.
Furosemide has also been studied for its potential effects on vascular function.
Some of its early hemodynamic effects may occur before substantial urine production develops.
These effects have contributed to research into its action beyond simple fluid removal.
The drug can influence the renin-angiotensin-aldosterone system.
Loss of sodium and fluid can activate compensatory hormonal mechanisms that promote sodium retention and vasoconstriction.
This physiological response is important in understanding the broader effects of loop diuretics.
Uses:
The diuretic effect of this product is a strong and short,it is a potent diuretic for the treatment of edema caused by heart, liver, kidney and other diseases, in particular, the base cases which other diuretics are invalid to;it can be used to treat acute pulmonary edema, brain edema , acute renal failure and high blood pressure and other diseases; in combination with fluid infusion, the product can promote poison excretion.
Furosemide is primarily used as a loop diuretic to increase urine production and promote the removal of excess sodium and water from the body.
Furosemide is widely used in medical practice when fluid accumulation occurs because of cardiovascular, renal, or hepatic conditions.
The drug is available in several pharmaceutical formulations for different clinical requirements.
Furosemide is commonly used to treat edema associated with congestive heart failure.
Heart failure can cause sodium and water retention, resulting in swelling and fluid congestion.
By increasing urinary sodium and water excretion, furosemide helps reduce this excess fluid.
Furosemide is also used for peripheral edema, particularly when fluid accumulates in the legs, ankles, or other tissues.
The diuretic effect decreases excess extracellular fluid and can relieve swelling.
Treatment is adjusted according to the underlying condition and the patient's response.
Furosemide is used in the management of pulmonary edema.
When excess fluid accumulates in the lungs, patients can experience severe shortness of breath and respiratory distress.
In appropriate acute-care situations, intravenous furosemide may be used to promote rapid fluid removal.
Another important use is the treatment of edema associated with kidney disorders.
Kidney diseases can interfere with normal sodium and water elimination, resulting in fluid retention.
Furosemide can increase urinary fluid elimination when sufficient renal responsiveness remains.
Furosemide is used in patients with nephrotic syndrome when significant edema develops.
Protein loss through the kidneys can contribute to fluid accumulation in tissues.
Diuretic therapy may be used as part of an overall treatment plan to manage the resulting edema.
Furosemide is also used for edema associated with chronic kidney disease.
Reduced kidney function can make it difficult for the body to maintain normal fluid balance.
Higher doses may sometimes be required because the delivery of the drug to its renal site of action can be reduced.
Furosemide can be used to manage fluid overload in patients with impaired renal function.
Its purpose in this setting is primarily to increase urine output and remove excess fluid.
The treatment response depends on the remaining functional capacity of the kidneys.
Another established use is the treatment of hepatic edema and ascites.
Advanced liver disease can cause sodium and water retention and the accumulation of fluid within the abdominal cavity.
Furosemide may be used, often alongside other therapies, to help control this fluid accumulation.
Furosemide is sometimes used together with spironolactone in the management of ascites associated with liver disease.
The two drugs act through different mechanisms and can provide complementary effects on sodium and water balance.
Electrolytes and kidney function require appropriate monitoring during combined treatment.
Furosemide is also used for hypertension in selected patients.
Furosemides ability to increase sodium and water excretion can reduce circulating fluid volume and contribute to lower blood pressure.
However, other classes of antihypertensive medicines are generally preferred for uncomplicated long-term hypertension.
It can be particularly useful for blood-pressure management when hypertension occurs together with significant fluid retention or impaired kidney function.
In such circumstances, controlling excess fluid may be an important part of overall treatment.
The choice of diuretic depends on the patient's clinical condition.
Furosemide has been used in acute decompensated heart failure.
Patients with acute worsening of heart failure may develop severe congestion and fluid accumulation.
Intravenous loop-diuretic therapy can be used to reduce congestion when clinically appropriate.
Furosemide is also used for volume overload in hospitalized patients.
Patients receiving intravenous fluids, experiencing organ dysfunction, or developing severe fluid retention may require pharmacological fluid removal.
Furosemide can be administered intravenously when oral treatment is inadequate or unsuitable.
Furosemide can be used in critical-care medicine for selected patients with substantial fluid accumulation.
Its strong diuretic action allows clinicians to increase urine production when appropriate.
Treatment is accompanied by monitoring of fluid balance, blood pressure, kidney function, and electrolytes.
Another use is the management of fluid overload associated with certain cardiac disorders.
Excessive circulating volume can increase the workload on the heart and contribute to congestion.
Furosemide helps reduce this volume through increased renal sodium and water excretion.
Furosemide is also used in acute kidney and cardiorenal management when fluid accumulation is a major clinical problem.
It can increase urine output in patients who retain some diuretic responsiveness.
However, increasing urine production does not by itself reverse underlying kidney injury.
Furosemide can be used as part of treatment for hypercalcemia in selected clinical circumstances.
Loop diuretics increase urinary calcium excretion, which can contribute to calcium removal.
This application requires adequate hydration and careful medical monitoring and is not appropriate as a routine self-treatment.
Furosemide has historically been used in forced diuresis protocols, although such applications are highly specialized and are not appropriate for routine poisoning treatment.
Increasing urine production does not reliably accelerate elimination of every toxic substance.
Modern toxicology practice therefore uses substance-specific treatments rather than indiscriminate forced diuresis.
The drug is also used in veterinary medicine.
Veterinarians may prescribe furosemide for animals experiencing congestive heart failure, pulmonary edema, or other conditions associated with excessive fluid accumulation.
Furosemide is particularly well established in veterinary cardiovascular medicine.
Furosemide is commonly used in equine medicine.
Veterinarians may use it in horses for certain cardiovascular and respiratory conditions.
The drug's diuretic and physiological effects make it an important veterinary therapeutic agent.
Furosemide is also used in canine and feline medicine.
Dogs and cats with congestive heart failure may receive furosemide to reduce pulmonary or systemic congestion.
Veterinary dosing and monitoring are determined according to the species, body weight, kidney function, and clinical condition.
Furosemide has an important application in veterinary performance and equine research because of its effects on fluid balance and respiratory physiology.
Furosemides use in animals involved in competition may be regulated by relevant sporting authorities.
Veterinary administration therefore needs to comply with applicable competition rules.
Furosemide is used as a pharmacological research tool in renal physiology.
Researchers administer it experimentally to inhibit the NKCC2 transporter in the thick ascending limb of the nephron.
This allows scientists to investigate sodium, potassium, chloride, calcium, and magnesium transport.
Furosemide is widely used in kidney transporter research.
Because furosemide specifically interferes with NKCC2 activity, it can help researchers determine the contribution of this transporter to renal electrolyte handling.
This makes it a standard experimental compound in nephrology and physiology studies.
Furosemide is also used in research on urine concentration mechanisms.
The thick ascending limb contributes to the medullary concentration gradient required for concentrated urine formation.
Inhibition of NKCC2 with furosemide allows researchers to investigate this process.
Furosemide is used in pharmacology experiments examining the relationship between drug concentration and diuretic response.
Researchers can measure urine volume and electrolyte excretion after controlled administration.
These studies provide information about pharmacodynamic behavior.
Furosemide is used in pharmacokinetic research to study drug absorption, distribution, metabolism, and elimination.
Blood and urine samples can be analyzed to determine drug concentrations over time.
These data are used to evaluate exposure and renal handling.
Furosemide is also used in pharmaceutical formulation research.
Because furosemide has relatively limited aqueous solubility and variable oral absorption, it provides a useful model for investigating drug-delivery strategies.
Researchers study particle engineering, dissolution enhancement, and alternative dosage forms.
Furosemide is used in pharmaceutical quality-control laboratories.
Manufacturers analyze tablets, solutions, and injectable products to confirm the identity and concentration of the active pharmaceutical ingredient.
Validated analytical procedures help ensure consistency between production batches.
Furosemide is also used as a reference standard in chromatographic analysis.
Known quantities of furosemide can be used to calibrate analytical instruments and validate quantitative methods.
HPLC and related techniques are commonly applied for this purpose.
Furosemide is used in stability studies of pharmaceutical products.
Researchers monitor the compound under different temperature, humidity, light, and pH conditions.
The resulting data help establish appropriate storage conditions and product shelf life.
The drug is also used in drug-development research as a model compound for studying poorly water-soluble active pharmaceutical ingredients.
Researchers can evaluate approaches such as nanosizing, solid dispersions, complexation, and other formulation technologies.
The knowledge obtained can be applied to other pharmaceutical compounds with similar solubility challenges.
Furosemide has an important role in anti-doping analysis.
Furosemide is classified as a prohibited diuretic and masking agent under the World Anti-Doping Agency's prohibited-substance framework.
Sports laboratories can analyze biological samples for furosemide using sensitive analytical methods.
Furosemide is used in analytical toxicology to identify and quantify furosemide in biological samples.
Chromatographic and mass-spectrometric methods can detect the drug at low concentrations.
Such analysis may be relevant to clinical, forensic, and anti-doping investigations.
Furosemide is also used in clinical laboratory research examining relationships between drug exposure and electrolyte excretion.
Researchers can evaluate changes in urinary sodium, potassium, calcium, and magnesium following administration.
These studies provide insight into renal drug responses.
Furosemide has been used in experimental cardiovascular research to investigate the relationship between fluid volume and cardiac function.
Removing excess sodium and water changes preload and circulatory pressures.
This allows researchers to study cardiorenal interactions under controlled conditions.
Furosemide is also relevant to heart-kidney interaction studies.
Heart failure and kidney dysfunction can reinforce each other through disturbances in fluid and sodium balance.
Furosemide provides a pharmacological means of modifying this balance in research and clinical settings.
Furosemide is used in studies of diuretic resistance.
Researchers investigate why some patients with chronic fluid overload have a reduced response to standard doses of loop diuretics.
These investigations include renal transporter adaptation, impaired drug delivery, and neurohormonal mechanisms.
Furosemide can also be used in research involving sequential nephron blockade.
Researchers study combinations of diuretics acting at different nephron segments to understand how sodium reabsorption can be inhibited at multiple sites.
This approach is particularly relevant to difficult-to-manage fluid overload.
Another use is in experimental models of pulmonary congestion.
Researchers can examine how diuresis affects lung fluid, circulatory pressures, and respiratory function.
Such studies contribute to understanding the management of acute and chronic fluid overload.
Furosemide is also used in medical education.
It provides a classic example of a drug that acts on a specific renal transporter and produces systemic changes in fluid and electrolyte balance.
Furosemide is therefore frequently discussed in pharmacology, medicine, pharmacy, nursing, and physiology courses.
In pharmaceutical chemistry, furosemide is used as an example of a sulfonamide-containing medicinal compound.
Furosemide structure demonstrates how different functional groups influence drug activity and physicochemical properties.
It is also useful for teaching structure-activity relationships and drug analysis.
Furosemide uses of furosemide are the treatment of edema, fluid overload, congestive heart failure, pulmonary edema, renal-associated fluid retention, and liver-associated ascites.
Beyond clinical medicine, it is extensively used in veterinary medicine, renal physiology, pharmaceutical formulation, quality control, pharmacokinetic research, analytical chemistry, and anti-doping analysis.
Furosemides broad scientific importance comes from its well-characterized inhibition of the renal NKCC2 transporter and its strong, measurable effects on sodium and water excretion.
Furosemide is used to manage acute fluid overload when rapid removal of excess water and sodium is clinically necessary.
Furosemides strong diuretic activity can produce a substantial increase in urine output in responsive patients.
This makes it particularly useful in hospital settings where fluid balance must be controlled closely.
Furosemide is used in the treatment of cardiac edema associated with different forms of heart disease.
Reduced cardiac efficiency can activate mechanisms that cause the kidneys to retain sodium and water.
Furosemide counteracts this retention by increasing renal sodium and fluid excretion.
Furosemide is used to reduce venous and systemic congestion in patients with heart failure.
Excess circulating volume can increase venous pressure and contribute to swelling and shortness of breath.
Diuretic therapy helps reduce this excess volume and associated congestion.
Furosemide can be used in patients with right-sided heart failure when fluid retention develops.
Right-sided cardiac dysfunction can contribute to peripheral edema and systemic venous congestion.
Increasing sodium and water elimination can help control these manifestations.
Furosemide is also used for generalized edema, in which excess fluid accumulates throughout multiple areas of the body.
Generalized edema can occur in severe cardiac, renal, or hepatic disorders.
Furosemide may be incorporated into treatment when fluid removal is clinically appropriate.
Furosemide can be used to control ascites, particularly when associated with chronic liver disease.
Ascites involves accumulation of fluid within the abdominal cavity and can cause considerable abdominal distension.
Diuretic treatment helps increase sodium and water elimination and can reduce the volume of retained fluid.
Furosemide may be used alongside aldosterone antagonists in certain ascites-management strategies.
Combining different diuretic mechanisms can improve sodium excretion while helping clinicians manage electrolyte balance.
The specific combination and dosing require medical supervision.
Furosemide is used for edema associated with severe protein-loss disorders.
Conditions that cause substantial loss of plasma proteins can promote movement of fluid into tissues.
Diuretic treatment can help manage the resulting fluid accumulation when appropriate.
Furosemide can be used in glomerular kidney diseases when significant edema develops.
Kidney disorders affecting filtration and protein handling can cause sodium and water retention.
Furosemide can help increase urinary fluid elimination in responsive patients.
Furosemide is also used in advanced chronic kidney disease to help manage volume overload.
As kidney function declines, the kidneys may become less capable of excreting sodium and water.
Loop diuretics can remain useful because they act at a nephron site with substantial sodium-reabsorptive capacity.
Safety Profile:
Poison by intravenous route, moderately toxic by ingestion and intraperitoneal routes.
Human systemic effects by intravenous route: change in the sensitivity of the ear to sound, tinnitus, unspecified effects on the heart, constriction of the arteries, a decrease in urine volume, interstitial nephritis, metabolic alkalosis, pulse rate decrease, fall in blood pressure.
Ingestion can damage the liver. Experimental teratogenic and reproductive effects.
Questionable carcinogen with experimental carcinogenic effects, human mutation data reported.
Furosemide is a pharmacologically active pharmaceutical compound that can cause adverse effects when used incorrectly, taken in excessive amounts, or administered without appropriate medical supervision.
Furosemides primary hazard is excessive loss of water and electrolytes because it strongly increases renal sodium and water excretion.
The severity of adverse effects depends on the dose, duration of treatment, route of administration, kidney function, and individual patient factors.
Furosemide can cause dehydration when excessive amounts of fluid are removed from the body.
Symptoms may include thirst, dry mouth, weakness, dizziness, and reduced urine output in severe cases.
Patients receiving strong diuretic therapy may therefore require monitoring of fluid balance.
Excessive fluid removal can also cause hypovolemia, meaning a reduction in circulating blood volume.
Significant volume depletion can result in low blood pressure and reduced blood flow to important organs.
Furosemide risk is particularly relevant when high doses are administered or when the patient is already dehydrated.
Supply of Furosemide:
For further information about Furosemide, including available product grades, technical specifications, application suitability and supply options, please contact Ataman Kimya.
